Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2022 / N 1

Эффективность стандартной терапии сердечно-сосудистых заболеваний при COVID-19: гипотезы, свидетельства и доказательства
С.Р. Гиляревский, М.В. Голшмид, Н.Г. Бенделиани, И.М. Кузьмина

Список литературы

1. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. The Lancet. 2021;398(10300):599-607. DOI: 10.1016/S0140-6736(21)00896-5
2. Sidney S, Lee C, Liu J, Khan SS, Lloyd-Jones DM, Rana JS. Age-adjusted mortality rates and age and risk-associated contributions to change in heart disease and stroke mortality, 2011–2019 and 2019–2020. JAMA Network Open. 2022;5(3):e223872. DOI: 10.1001/jamanetworkopen.2022.3872
3. Cohen K, Ren S, Heath K, Dasmariñas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022;376:e068414. DOI: 10.1136/bmj-2021-068414
4. Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 – epidemiology, pathophysiology, and diagnosis. European Heart Journal. 2022;43(11):1033-1058. DOI: 10.1093/eurheartj/ehab696
5. Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, Pignatelli P, Pastori D. Features of severe COVID-19: a systematic review and meta-analysis. European Journal of Clinical Investigation. 2020;50(10):e13378. DOI: 10.1111/eci.13378
6. Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 – care pathways, treatment, and follow-up. European Heart Journal. 2022;43(11):1059-1103. DOI: 10.1093/eurheartj/ehab697
7. Basille D, Plouvier N, Trouve C, Duhaut P, Andrejak C, Jounieaux V. Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia: a cohort study. Lung. 2017;195(2):201-208. DOI: 10.1007/s00408-016-9973-1
8. Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Frontiers in Immunology. 2017;8:261. DOI: 10.3389/fimmu.2017.00261
9. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ. 2011;342:d1642. DOI: 10.1136/bmj.d1642
10. Fleming DM, Verlander NQ, Elliot AJ, Zhao H, Gelb D, Jehring D, Nguyen-Van-Tam JS. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006. Epidemiology & Infection. 2010;138(9):1281-1288. DOI: 10.1017/S0950268810000105
11. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver International. 2020;40(5):998-1004. DOI: 10.1111/liv.14435
12. Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R; Reggio Emilia COVID-19 Working Group. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PLoS One. 2020;15(8):e0238281. DOI: 10.1371/journal.pone.0238281
13. Kim DW, Byeon KH, Kim J, Cho KD, Lee N. The correlation of comorbidities on the mortality in patients with COVID-19: an observational study based on the Korean National Health Insurance Big Data. Journal of Korean Medical Science. 2020;35(26):e243. DOI: 10.3346/jkms.2020.35.e243
14. Laffin LJ, Kaufman HW, Chen Z, Niles JK, Arellano AR, Bare LA, Hazen SL. Rise in blood pressure observed among US adults during the COVID-19 pandemic. Circulation. 2022;145(3):235-237. DOI: 10.1161/CIRCULATIONAHA.121.057075
15. Gupta AK, Arshad S, Poulter NR. Compliance safety and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407. DOI: 10.1161/HYPERTENSIONAHA.109.139816
16. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903-1913. DOI: 10.1016/s0140-6736(02)11911-8
17. McFarlane E, Linschoten M, Asselbergs FW, Lacy PS, Jedrzejewski D, Williams B; CAPACITY-COVID Consortium. The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19. Hypertension Reseasrch. 2022;45(5):834-845. DOI: 10.1038/s41440-022-00893-5
18. Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, Feldman A, D’Andréa Saba Arruda G, de Albuquerque DC, Camiletti AS, de Sousa AS, de Paula TC, Giusti KGD, Domiciano RAM, Noya-Rabelo MM, Hamilton AM, Loures VA, Dionísio RM, Furquim TAB, De Luca FA, Dos Santos Sousa ÍB, Bandeira BS, Zukowski CN, de Oliveira RGG, Ribeiro NB, de Moraes JL, Petriz JLF, Pimentel AM, Miranda JS, de Jesus Abufaiad BE, Gibson CM, Granger CB, Alexander JH, de Souza OF; BRACE CORONA Investigators. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325(3):254-264. DOI: 10.1001/jama.2020.25864
19. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, Andrade-Villanueva JF, Barbagelata A, Cristodulo-Cortez R, Díaz-Cucho OA, Spaak J, Alfonso CE, Valdivia-Vega R, Villavicencio-Carranza M, Ayala-García RJ, Castro-Callirgos CA, González-Hernández LA, Bernales-Salas EF, Coacalla-Guerra JC, Salinas-Herrera CD, Nicolosi L, Basconcel M, Byrd JB, Sharkoski T, Bendezú-Huasasquiche LE, Chittams J, Edmonston DL, Vasquez CR, Chirinos JA. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. The Lancet. Respiratory Medicine. 2021;9(3):275-284. DOI: 10.1016/S2213-2600(20)30558-0
20. UMPIRE: Multidrug ‘Polypill’ Improves Adherence, BP, Cholesterol. TCTMD. NEWS. Conference News. AHA, 2012. Available from: https://www.tctmd.com/news/debate-continues-auc Accessed 2022 May 30.
21. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nature Medicine. 2021;27(4):601-615. DOI: 10.1038/s41591-021-01283-z
22. Ståhlberg M, Reistam U, Fedorowski A, Villacorta H, Horiuchi Y, Bax J, Pitt B, Matskeplishvili S, Lüscher TF, Weichert I, Thani KB, Maisel A. Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome. The American Journal of Medicine. 2021;134(12):1451-1456. DOI: 10.1016/j.amjmed.2021.07.004
23. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220-232. DOI: 10.1016/S0140-6736(20)32656-8
24. Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. Journal of Internal Medicine. 2019;285(4):352-366. DOI: 10.1111/joim.12852
25. Johansson M, Ståhlberg M, Runold M, Nygren-Bonnier M, Nilsson J, Olshansky B, Bruchfeld J, Fedorowski A. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC. Case Reports. 2021;3(4):573-580. DOI: 10.1016/j.jaccas.2021.01.009
26. Yang T, Jiang Y, Hao Y, Zhou S, Xu X, Qu B, Lin X, Ma T. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertension Research. 2017;40(1):79-86. DOI: 10.1038/hr.2016.101
27. Korhonen MJ, Robinson JG, Annis IE, Hickson RP, Bell JS, Hartikainen J, Fang G. Adherence tradeoff to multiple preventive therapies and all-cause mortality after acute myocardial infarction. Journal of the American College of Cardiology. 2017;70(13):1543-1554. DOI: 10.1016/j.jacc.2017.07.783
28. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet. 1999;353(9146):9-13. DOI: 10.1016/S0140-6736(98)11181-9
29. Vanoli E, Dei Cas L, Willenheimer R. Sudden death prevention in heart failure: the case of CIBIS III. Heart International. 2006;2(2):73. DOI: 10.4081/hi. 2006.73
30. Edelmann F, Musial-Bright L, Gelbrich G, Trippel T, Radenovic S, Wachter R, Inkrot S, Loncar G, Tahirovic E, Celic V, Veskovic J, Zdravkovic M, Lainscak M, Apostolović S, Neskovic AN, Pieske B, Düngen HD; CIBIS-ELD Investigators and Project Multicenter Trials in the Competence Network Heart Failure. Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: insights from the CIBIS-ELD Trial. JACC. Heart Failure. 2016;4(2):140-149. DOI: 10.1016/j.jchf.2015.10.008
31. Fonarow GC. Managing the patient with diabetes mellitus and heart failure: issues and considerations. The American Journal of Medicine. 2004;116(Suppl 5A):76S-88S. DOI: 10.1016/j.amjmed.2003.10.022
32. Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. European Heart Journal. Supplements. 2009;11(Suppl A):A21-25. DOI: 10.1093/eurheartj/sup001
33. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet. 2003;362(9386):782-788. DOI: 10.1016/s0140-6736(03)14286-9
34. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. The New England Journal of Medicine. 2008;358(18):1887-1898. DOI: 10.1056/NEJMoa0801369
35. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 2005;366(9489):895-906. DOI: 10.1016/S0140-6736(05)67185-1
36. Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet. 2007;370(9590):829-840. DOI: 10.1016/S0140-6736(07)61303-8
37. Ferrari R; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Archives of Internal Medicine. 2006;166(6):659-666. DOI: 10.1001/archinte.166.6.659
38. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, Kluft C, Blann A, Cokkinos D, Ferrari R; EUROPA Investigators; PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovascular Research. 2007;73(1):237-246. DOI: 10.1016/j.cardiores.2006.10.021
39. Boytsov SA, Burtsev YP, Khomitskaya YV, Karpov YA; STYLE study investigators. Effectiveness and tolerability of the single-pill combination of bisoprolol and perindopril in patients with arterial hypertension and stable coronary artery disease in daily clinical practice: the STYLE study. Advances in Therapy. 2021;38(6):3299-3313. DOI: 10.1007/s12325-021-01754-2
40. Лутай М.И., Голiкова И.П. Ефективнiсть лiкування пацiентiв зi стабiльною iшемiчною хворобою серця та супутньою артерiальною гiпертензiею: результати багатоцентрового дослiдження ПРЕСТОЛ. Украiнський кардiологiчний журнал. 2019;26(1):19-30. [Lutai MI, Golikova IP. Efficacy of treatment of patients with stable coronary heart disease and concomitant arterial hypertension: results of the multicenter PRESTOL study. Ukrainian Journal of Cardiology. 2019;26(1):19-30. (In Ukranian).] DOI:10.31928/1608-635X-2019.1.1930
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]